FindTrial
Sign In

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00089869
Enrollment
Unknown
Registered
2004-08-18
Start date
Unknown
Completion date
Unknown
Last updated
2006-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa

Interventions

DRUGolanzapine
DRUGatomoxetine
DRUGplacebo

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Must have a clinical diagnosis of Schizophrenia * Must be at least 18 years of age and not older than 55 years of age * Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks * Women of childbearing potential must be using a medically accepted means of contraception * Must be able to swallow capsules

Exclusion criteria

* Has serious health problems other than Schizophrenia * Takes an antidepressant for depression * Takes insulin for diabetes * Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026